🧬 BioMed Pulse · 2026-09-19 02:01 UTC
BIOMED PULSE
Saturday, September 19, 2026 — Daily Briefing on Longevity, Viruses & New Cures
⚡ TL;DR
The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the country — and it is still accelerating. [1]
Mood: Alarming on the outbreak front; longevity science is quietly productive with fresh findings on senescence, bone repair, and aging metabolism.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO EBOLA — DRC (ACTIVE, ESCALATING)
- As of September 10, 2026, WHO confirms 61 affected health zones in six DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo; the Kayna health zone in North Kivu is newly added since the August 28 update. [1]
- WHO designates this the largest Ebola outbreak ever reported in the DRC, outpacing all previous outbreaks in both scale and speed of geographic spread. [2] [1]
- Cross-border transmission to Uganda was confirmed earlier in the outbreak; sustained urban and community transmission is now the dominant driver. [3] [1]
- Cumulative confirmed cases surpassed 2,124 with 828 deaths as of July 15, 2026; figures have continued to rise through the August and September reports. [4] [3]
- The causative agent is Bundibugyo virus (BVD), a distinct Ebola species first identified in Uganda in 2007, with a historically lower but still significant case fatality ratio compared to Ebola virus disease. [5] [6]
- CDC mobilized international response on May 17, 2026, and enhanced Ebola airport screening was activated at Washington-Dulles and Atlanta international airports in May 2026. [7] [8]
ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (ONGOING MONITORING)
- WHO's fifth Disease Outbreak News on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius was published July 2, 2026, tracking additional confirmed cases since the original May 2 notification. [9]
- CDC's most recent transcript update on the hantavirus response is dated June 24, 2026, with monitoring continuing. [10]
- Andes hantavirus causes hantavirus pulmonary syndrome, a severe and potentially fatal respiratory illness; person-to-person transmission of ANDV is documented, distinguishing it from other hantavirus species.
ANIMAL RABIES — UNITED STATES
- CDC issued a statement on September 10, 2026, noting a recent increase in animal rabies activity and associated human exposure incidents across the United States.
WEST NILE VIRUS — UNITED STATES
- CDC reported an early and record-breaking 2026 West Nile virus season as of July 1, 2026, urging mosquito-bite prevention measures.
CYCLOSPORIASIS — UNITED STATES
- Cyclospora cayetanensis infections linked to shredded iceberg lettuce at Taco Bell locations sickened 1,644 people across at least nine states as of late July 2026; four additional states were added to the outbreak scope on July 24.
🧬 LONGEVITY & AGING
HIGH-DOSE INFLUENZA VACCINE AND FRAILTY
- A prespecified analysis of the randomized DANFLU-2 trial published in Lancet Healthy Longevity finds that high-dose influenza vaccine outperforms standard-dose against hospitalization specifically in older adults with elevated frailty risk — meaning the sickest elderly benefit most from the stronger shot.
- A linked commentary frames this as the "frailty-influenza paradox": frail individuals face greater risk from infection yet paradoxically show greater relative benefit from the high-dose formulation.
UROLITHIN A AND GLUCOSE METABOLISM IN OLDER ADULTS
- An NCT06274749 randomized triple-masked controlled trial (registered ClinicalTrials.gov) is evaluating whether Urolithin A supplementation improves glucose metabolism in healthy adults aged 55 and older, targeting the age-related decline in pancreatic insulin secretion.
- Urolithin A is a gut-microbiome-derived metabolite of polyphenols found in pomegranates and berries; it is known to activate mitophagy (clearance of damaged mitochondria), a pathway central to cellular aging.
SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) CHARACTERIZATION
- A Europe PMC study published in Methods in Molecular Biology describes multiplex assay methods to characterize the SASP — the cocktail of inflammatory signals released by senescent cells — in both primary and iPSC-derived skin cells, providing standardized tools for senolytic drug research.
IONIZING RADIATION AND CELLULAR SENESCENCE
- Research published in Genes and Disease shows that ionizing radiation induces senescence in dermal papilla cells (hair follicle stem cell niche) by suppressing the FOXM1-KIF20A signaling pathway, potentially explaining radiation-associated hair loss and accelerated skin aging.
MRNA NANOPARTICLES FOR AGE-RELATED BONE REPAIR
- A study in Bioactive Materials describes a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis in aging bone cells, promoting repair of age-related bone defects in preclinical models — an early but notable convergence of mRNA technology and geroscience.
YOUNG PLASMA EXOSOMES AND ALZHEIMER'S DISEASE
- A review in Bioactive Materials examines engineered exosomes derived from young plasma as a potential therapeutic strategy in Alzheimer's disease, proposing they may transfer neuroprotective signals and modulate amyloid and tau pathology.
HIP FRACTURE SURGERY ANAESTHESIA IN OLDER PATIENTS
- A multicenter randomized clinical trial published in Lancet Healthy Longevity and conducted in Germany compared spinal versus general anaesthesia in older hip fracture patients, directly addressing a gap in geriatric surgical safety evidence.
- A linked editorial asks whether accumulated trial data now justify a definitive practice standard for anaesthesia choice in this high-risk, high-volume older-adult surgical population.
DEPRESCRIBING TRIAL METHODOLOGY
- Two letters in Lancet Healthy Longevity argue that deprescribing trials (studies on safely stopping medications in older adults) require a rationale-first framework — identifying the biological mechanism before choosing trial design — to avoid null results from poorly constructed study arms.
💊 NEW CURES & APPROVALS
PIXCLARA (FLORETYROSINE F-18) — TELIX PHARMACEUTICALS US INC
- FDA original approval (NDA218592) for Pixclara, a fluorine-18 labeled amino acid PET imaging agent (floretyrosine F-18) sponsored by Telix Pharmaceuticals US Inc, used to visualize amino acid uptake in brain tumors to guide diagnosis and treatment planning.
DASATINIB — MSN PHARMACEUTICALS
- FDA original ANDA approval (ANDA219579) for a generic formulation of dasatinib by MSN; dasatinib is a BCR-ABL/Src kinase inhibitor used in chronic myeloid leukemia and is also being investigated as a senolytic agent in aging-related research.
EPINEPHRINE — ZYDUS PHARMACEUTICALS
- FDA original ANDA approval (ANDA219832) for a new generic epinephrine injectable formulation by Zydus Pharmaceuticals, expanding supply of this critical emergency anaphylaxis and cardiac resuscitation medication.
COLISTIMETHATE SODIUM — SAGENT PHARMACEUTICALS INC
- FDA supplemental approval (ANDA201365) for colistimethate sodium by Sagent Pharmaceuticals, a last-resort antibiotic used against extensively drug-resistant Gram-negative bacteria including carbapenem-resistant organisms.
🧪 CLINICAL TRIALS
NEOANTIGEN T-CELL THERAPY FOR HEMATOLOGIC MALIGNANCIES — NCT06904066
- A ClinicalTrials.gov study (updated September 18, 2026) is testing autologous T cells transduced with retroviral vectors expressing T-cell receptors (TCRs) targeting participant-specific neoantigens — mutations unique to each patient's cancer — in leukemias including those with TP53 or RAS mutations, which are among the hardest to treat.
MYELOMATCH AML TRIAL — NCT05554406
- A Phase II platform trial (updated September 18, 2026) is comparing standard cytarabine plus daunorubicin against three experimental regimens including CPX-351 (liposomal daunorubicin/cytarabine) for newly diagnosed high-risk acute myeloid leukemia patients, a disease primarily affecting older adults.
HIV VACCINE BOOSTER TRIAL — NCT06665646
- A ClinicalTrials.gov study (updated September 18, 2026) is evaluating three injections of CD40.HIVRI.Env (VRIPRO) adjuvanted with Hiltonol (poly-ICLC) at weeks 0, 4, and 24 in 40 HIV-negative adults aged 18-60 who previously participated in HVTN 706, testing whether boosting prior immunity improves responses.
UROLITHIN A IN AGING ADULTS — NCT06274749
- A randomized triple-masked controlled trial at ClinicalTrials.gov (updated September 18, 2026) is assessing Urolithin A supplementation for glucose metabolism improvement in adults aged 55 and over, targeting a mitophagy-linked mechanism of metabolic aging.
FUNCTIONAL REACH TEST MINIMUM CLINICALLY IMPORTANT DIFFERENCE — NCT05853406
- A study (updated September 18, 2026) is determining the minimal clinically important difference for the Functional Reach Test in elderly participants, a standard fall-risk balance assessment, using both statistical and anchor-based methods.
DECISION SUPPORT FOR AFRICAN AMERICAN FAMILIES WITH DEMENTIA — NCT05139290
- The DECIDE Dyads and Families trial (updated September 18, 2026) is testing a tailored decision-support program for adult daughters making healthcare decisions for parents living with memory loss, with a focus on improving quality of life in African American families.
📢 PUBLIC HEALTH
DRUG-RESISTANT BACTERIA RISE — CDC REPORT
- A CDC report released September 23, 2026 (in the data window) found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing the urgency of antimicrobial stewardship; specific organisms were not named in the available summary.
NEWBORN SYPHILIS — 12TH CONSECUTIVE YEAR OF INCREASE
- New CDC data released September 24, 2025 show U.S. congenital syphilis cases rose for the 12th consecutive year in 2024, marking a sustained and worsening public health failure in prenatal screening and treatment access.
LISTERIA — ONGOING PREPARED MEALS OUTBREAK
- CDC continues to warn consumers to check refrigerators and freezers for recalled prepared meal products linked to an ongoing Listeria monocytogenes outbreak; new illnesses are still being reported despite recalls.
SALMONELLA — MORINGA LEAF PRODUCTS
- As of late May 2026, CDC and FDA were tracking a growing number of Salmonella illnesses and outbreaks linked to moringa leaf products including powdered supplements and capsules, with extensively drug-resistant strains identified and 65 cases in 28 states reported as of January 29, 2026, with further updates issued through May 2026.
RABIES DOG IMPORTATION RULES UPDATED
- CDC clarified and simplified the importation process for dogs from rabies-free and low-risk dog rabies countries to prevent re-introduction of dog rabies into the United States.
BIOMED PULSE is an informational briefing grounded in official public health and scientific sources. It is not medical advice. Consult a qualified healthcare provider for personal medical decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
- Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
- Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
- Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260919-02-v80 · 2026-09-19 02:01 UTC · pulse.uzylab.com